ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Topical Application of BMX-010 in Subjects With Acne Vulgaris.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03752242
Recruitment Status : Recruiting
First Posted : November 22, 2018
Last Update Posted : January 7, 2019
Sponsor:
Information provided by (Responsible Party):
BioMimetix JV, LLC

Brief Summary:
This is an exploratory Phase 2 trial of BMX-010 in patients with Acne Vulgaris which will be conducted in two parts. Up to 210 subjects with Acne Vulgaris will be enrolled.

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: BMX-010 Phase 2

Detailed Description:

Part A is designed to confirm the optimal formulation, strength, and dosing frequency of the study drug in patients with Acne. Up to 60 subjects will be enrolled in this part.

Part B is designed to be a randomized, double-blind trial studying the optimal formulation, strength, and dosing frequency of BMX-010 as determined in Part A, compared to Placebo in patients with Acne. Up to 150 subjects will be enrolled in this part. In both parts, adult subjects with Rosacea will be enrolled.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: In Part A, all subjects will receive study drug and this is Open Label. When Part A is complete, Part B will start and this will be double blind to participant and investigators.
Primary Purpose: Treatment
Official Title: An Exploratory Trial to Evaluate the Clinical Effectiveness of a Topical Application of BMX-010 in Subjects With Acne Vulgaris.
Actual Study Start Date : January 3, 2019
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : November 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: BMX-010 0.03%
Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
Drug: BMX-010
Safety and efficacy of BMX-010 in topical treatment of acne.

Experimental: BMX-010 0.1%
Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
Drug: BMX-010
Safety and efficacy of BMX-010 in topical treatment of acne.




Primary Outcome Measures :
  1. Determine whether the optimum frequency of topical application of BMX-010 0.03% is once per day or twice per day for a treatment interval of 7 to 28 days. [ Time Frame: 28 days ]
    Assessed by change in the 5-point Investigator Global Assessment (IGA). This will be measured weekly from Days 1-28.

  2. Determine whether the optimum frequency of topical application of BMX-010 0.1% is once per day or twice per day for a treatment interval of 7 to 28 days. [ Time Frame: 28 days ]
    Assessed by change in the 5-point Investigator Global Assessment (IGA). This will be measured weekly from Days 1-28.

  3. Determine if BMX-010 cream or gel provides better efficacy in the clearing of acne. [ Time Frame: 43 days ]
    Assessed by change in the 5-point Investigator Global Assessment (IGA). This will be measured weekly from Days 1-28, followed by a final assessment two weeks after dosing ends at day 43.

  4. Evaluate the efficacy of BMX-010 in treatment of Acne Vulgaris. [ Time Frame: 43 days ]
    Assessed by change in the 5-point Investigator Global Assessment (IGA). This will be measured weekly from Days 1-28, followed by a final assessment two weeks after dosing ends at day 43.


Secondary Outcome Measures :
  1. Document, as possible, the clinical effects of BMX-010 in subjects with Acne Vulgaris through clinical photography. [ Time Frame: 43 days ]
    If consented by the patient, photos will be taken at each study visit.

  2. Assess the mean percent reduction change in inflammatory and noninflammatory lesion counts from baseline to end of study. [ Time Frame: 43 days ]
    Inflammatory and non-inflammatory lesions will be counted at each study visit.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, at least 18 years of age;
  2. A clinical diagnosis of mild to severe facial Acne Vulgaris; Subjects may also have acne at other body sites;
  3. Screening and Baseline IGA score > 2 (greater than or equal to 2);
  4. Willing to refrain from using any topical or systemic treatments for inflammatory skin disease, other than the investigational product;
  5. Candidate for topical treatment of Acne;
  6. If a cleanser, moisturizer or sunscreen is needed during the study, Subjects must be willing to use only allowed cleansers, moisturizers, sunscreens, or moisturizer/sunscreen combination products. If the subject wears makeup they must agree to use non-comedogenic makeup.
  7. Females of child-bearing potential must have a negative urine pregnancy test within 48 hours prior to the first drug administration;
  8. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the investigator (for example, oral contraceptive pills plus a barrier method) through the trial and for 1 month thereafter to be eligible for, and continue participation in, the study;
  9. Ability to complete the study in compliance with the protocol, including agreement in writing to apply study product only to the assigned areas; and
  10. Ability to understand and provide written informed consent.

Exclusion Criteria:

  1. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive;
  2. Use of androgen receptor blockers (such as spironolactone or flutamide);
  3. Severe cystic acne, acne conglobate, acne fulminans, or secondary acne;
  4. Use of phototherapy devices, energy-based devices, adhesive cleansing strips, or cosmetic procedures (e.g., facials, peeling, comedo extraction) in the past week;
  5. Presence of beard or excessive facial hair at Screening which would interfere with the study treatments or study assessments and refusal to remove for duration of study;
  6. Prior or current concomitant therapies that would interfere with assessments in the study;
  7. Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study;
  8. Use of anti-inflammatory medications, salicylic acid; corticosteroids, antibiotics, antibacterials (including benzoyl peroxide-containing products [e.g., benzamycin]), retinoids; other topical acne treatments (e.g., photodynamic therapy, medicated soaps such as those containing benzoyl peroxide, salicylic acid, sulfur, or sodium sulfacetamide) in the past 2 weeks;
  9. Oral retinoid use (e.g., isotretinoin) within 6 months prior to baseline or vitamin A supplements greater than 10,000 units/day within 6 months of baseline;
  10. Concomitant skin disease that could confound clinical evaluations or increase risk to the subject;
  11. Use of medicated make-up (including anti-aging make-up) throughout the study;
  12. Use during the study of 1) systemic steroids, 2) topical retinoids to the face, 3) antibiotics known to impact acne, 4) immunosuppressive agents, or immunomodulators;
  13. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical antimycotics, 4) any topical acne treatments or 4) topical antibiotics;
  14. Use of medicated cleansers on the face (throughout the study);
  15. Use of topical astringents or abrasives, medical topical preparations (prescription and OTC products) within 2 days prior to Baseline and throughout the study;
  16. Systemic or skin infection requiring antimicrobial therapy;
  17. Systemic chemotherapy or radiotherapy within 4 weeks of the Baseline Visit;
  18. Immunocompromise of any cause, known human immunodeficiency virus infection, or acquired immunodeficiency syndrome;
  19. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator;
  20. Active drug or alcohol dependence;
  21. Significant acute or chronic medical, neurological, or psychiatric illness that, in the judgment of the investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study;
  22. Previous clinical trial participation for the indication being treated in this protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03752242


Contacts
Contact: Sara Penchev 720-613-4872 contact@bmxpharma.com

Locations
United States, Colorado
Colorado Skin Care Recruiting
Englewood, Colorado, United States, 80113
Contact: Kathryn Adams    303-740-4883    kathryn.adams@coskincare.com   
Sponsors and Collaborators
BioMimetix JV, LLC

Responsible Party: BioMimetix JV, LLC
ClinicalTrials.gov Identifier: NCT03752242     History of Changes
Other Study ID Numbers: BMX-DERM-203
First Posted: November 22, 2018    Key Record Dates
Last Update Posted: January 7, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases